Live Support
Prescribing Neulasta®
Neulasta® offers you and your patient a once-per-cycle treatment option to help reduce the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy with a clinically significant incidence of FN.
Dosing & Safety
Read the Neulasta® safety profile and administration details.
Interested in Neulasta® updates?
Thank You.
Subscriber Information
Please note: If at any time you decide you no longer wish to receive information by e-mail, you will be able to unsubscribe.
The personal information you supply to us will be shared with and among our business partners to provide you with products, programs, and services regarding Neulasta® and to conduct market research. Your information may be combined with additional information from this or other Amgen-sponsored programs in which you participate. Your information will be used only by Amgen and business service companies working with us, and will not be sold or rented. If in the future you no longer want to receive materials from Neulasta®, you may do so by following the unsubscribe link included in all such materials sent to you, or you may click here.
For further information about Amgen privacy practices, please visit wwwext.amgen.com/privacy/statement.html to review our Privacy Statement.
Indication
Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Important Safety Information
Do not administer Neulasta to patients with a history of serious allergic reactions to pegfilgrastim or Filgrastim.
Splenic rupture, including fatal cases, can occur following the administration of Neulasta. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving Neulasta.
Acute respiratory distress syndrome (ARDS) can occur in patients receiving Neulasta. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Neulasta for ARDS. Discontinue Neulasta in patients with ARDS.
Serious allergic reactions, including anaphylaxis, can occur in patients receiving Neulasta. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue Neulasta in patients with serious allergic reactions.
Severe sickle cell crises can occur in patients with sickle cell disorders receiving Neulasta. Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, the parent compound of pegfilgrastim.
The granulocyte colony-stimulating factor (G-CSF) receptor, through which pegfilgrastim and Filgrastim act, has been found on tumor cell lines. The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim is not approved, cannot be excluded.
Bone pain and pain in extremity occurred at a higher incidence in Neulasta-treated patients as compared with placebo-treated patients.
© 2011 Amgen Inc. All rights reserved. MC49791-B
